Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stomach and colorectal cancer: Identifying patients who are suitable for immunotherapy

04.06.2019

Scientists from Uniklinik RWTH Aachen, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases Heidelberg (NCT) have developed an adaptive algorithm that can predict instability in microsatellites based directly on images of tissue samples.

Changes in certain sections of the genetic material of cancer cells, so-called microsatellites, can provide an important indication of whether immunotherapy may be successful in a patient with stomach or colorectal cancer.


Tissue from a patient (a) with microsatellite instability (MSI) and a patient (b) with microsatellite stability (MSS).

Photo credits: Jakob Nikolas Kather

Scientists from Uniklinik RWTH Aachen, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases Heidelberg (NCT) have developed an adaptive algorithm that can predict instability in microsatellites based directly on images of tissue samples.

This could help to potentially identify patients at an early stage who could benefit from immunotherapy. The research results were published in the journal Nature Medicine.

Only a small number of patients with stomach or colorectal cancer respond to immunotherapy. Some tumors lead to changes in the genetic material, and this can cause mutations in the sections of the genome, referred to as “microsatellites”, that are frequently replicated.

This microsatellite instability (MSI) is a characteristic for distinguishing between different cancers of the gastrointestinal tract and determines whether patients with these diseases are able to respond well to immunotherapy with checkpoint inhibitors. Detecting these properties usually requires a genetic or immunohistochemical test, which requires additional costs and is not always automatically performed for every patient in clinical practice.

The scientists in Aachen and Heidelberg, in collaboration with international colleagues, showed that a computer-aided adaptable algorithm, based on the concept of “deep learning”, enables MSI to be directly diagnosed based on routinely available images of tissue samples without the need for additional laboratory tests.

“With our approach, we have the potential to test any patient with colorectal cancer for MSI automatically and cost-effectively, which allows us to provide the option of immunotherapy to a larger group of colorectal cancer patients,” says Jakob Nikolas Kather, physician and scientist at the Clinic for Gastroenterology, Metabolic Diseases and Internal Intensive Care (Medical Clinic III) at Uniklinik RWTH Aachen and member of staff at DKFZ and NCT Heidelberg.“This makes it possible to identify patients who may otherwise never be considered for immunotherapy. However, this approach must be reviewed in prospective studies,” adds Dirk Jäger, Medical and Executive Director of the Department of Medical Oncology at NCT Heidelberg.

Immunotherapy for cancer

Cancer immunotherapies with so-called checkpoint inhibitors, which can be seen as active agents that release the “brakes” of the immune system, have attracted considerable attention in recent years. For colorectal cancer, however, checkpoint inhibitors have thus far only been successful in “microsatellite instable” tumors. In the more common “microsatellite stable” cases of colorectal cancer, checkpoint inhibitors have not shown objective response rates in previous studies. It remains challenging to predict which patients can benefit from immunotherapy in daily practice. This makes it all the more important to identify patients at an early stage who could benefit from immunotherapy in day-to-day clinical treatment.

Artificial intelligence in medicine

Artificial intelligence and adaptable algorithms are becoming increasingly prominent in medicine. Technological support has been required for a long time. The relevant data are entered into the applications, thereby training the algorithm to analyze large amounts of data and medical images to enable more efficient and more accurate treatments, such as the automatic detection of cancer cells.

Original publication
Jakob Nikolas Kather, Alexander T. Pearson, Niels Halama, Dirk Jäger, Jeremias Krause, Sven H. Loosen, Alexander Marx, Peter Boor, Frank Tacke, Ulf Peter Neumann,
Heike I. Grabsch, Takaki Yoshikawa, Hermann Brenner, Jenny Chang-Claude,
Michael Hoffmeister, Christian Trautwein, Tom Luedde (2019) Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, https://www.nature.com/articles/s41591-019-0462-y

An image for the press release is available free of charge on the internet:
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/Meldungen/Bild...

Caption: Tissue from a patient (a) with microsatellite instability (MSI) and a patient (b) with microsatellite stability (MSS).

Notice for image material in press releases
The use of images is free of charge. The NCT Heidelberg permits one-time use in connection with coverage of the subject of the press release. Please list the photo credits: “Jakob Nikolas Kather”. The transmission of photographic material to third parties is only permitted after prior consultation with the NCT Press Office (Tel. 06221 56 5930, Email: friederike.fellenberg@nct-heidelberg.de). Use for commercial purposes is prohibited.

Press contact:
Dr. Friederike Fellenberg
National Center for Tumor Diseases Heidelberg (NCT)
Press and Public Relations
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 56-5930
Fax: +49 6221 56-5350
Email: friederike.fellenberg@nct-heidelberg.de
www.nct-heidelberg.de

Dr. Sibylle Kohlstädt
German Cancer Research Center (DKFZ)
Communications and Marketing
Im Neuenheimer Feld 280
69120 Heidelberg
Tel.: +49 6221 42-2843
Fax: +49 6221 42-2968
Email: s.kohlstaedt@dkfz.de
www.dkfz.de

Doris Rübsam-Brodkorb
Heidelberg University Hospital and Medical Faculty of the University of Heidelberg
Press and Public Relations
Im Neuenheimer Feld 672
69120 Heidelberg
Tel.: +49 6221 56-5052
Fax: +49 6221 56-4544
Email: doris.ruebsam-brodkorb@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de

Dr. Mathias Brandstädter
Leitung Unternehmenskommunikation
Uniklinik RWTH Aachen
Pauwelsstraße 30
52074 Aachen
Telefon: 0241 80-89893
Fax: 0241 80-3389893
mbrandstaedter@ukaachen.de

National Center for Tumor Diseases Heidelberg (NCT)
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital (UKHD) and German Cancer Aid. The NCT’s goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. This is true for both diagnosis and treatment, follow-up care or prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here, the patients benefit from an individual treatment plan prepared in interdisciplinary expert rounds, so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, the NCT Heidelberg has maintained a partner site in Dresden. The Hopp Children’s Cancer Center (KiTZ) was established in Heidelberg in 2017. The pediatric oncologists at KiTZ work together in parallel structures with the NCT Heidelberg.

German Cancer Research Center (DKFZ)
The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful.
The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Together with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic.
In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Heidelberg University Hospital
Heidelberg University Hospital (UKHD) is one of the most important medical centers in Germany; Heidelberg University’s Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 13,000 individuals and are involved in training and qualification. Every year approximately 65,000 patients are treated as inpatients and 56,000 as day patients in more than 50 specialized clinical departments with around 2,000 beds, with more than 1 million patients being treated as outpatients. Together with the German Cancer Research Center and German Cancer Aid, the Heidelberg University Hospital established The National Center for Tumor Diseases (NCT) Heidelberg as the leading oncology center of excellence in Germany. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present 3,700 aspiring physicians and doctors are studying in Heidelberg.

Uniklinik RWTH Aachen
The Uniklinik RWTH Aachen is a supramaximal care provider that combines patient-oriented medicine and nursing, teaching and research at an international level. With 36 specialist clinics, 25 institutes and five interdisciplinary units, the University Hospital covers the entire medical spectrum. Excellently qualified teams of doctors, nurses and scientists are competently committed to the health of the patients. The bundling of patient care, research and teaching in one central building offers the best conditions for intensive interdisciplinary exchange and close clinical and scientific networking. Around 7.000 employees provide patient-oriented medicine and care according to recognised quality standards. With 1.400 beds, the University Hospital treats around 50.000 inpatient and 200.000 outpatient cases per year.

Wissenschaftliche Ansprechpartner:

Jakob Nikolas Kather
Dirk Jäger

Originalpublikation:

Jakob Nikolas Kather, Alexander T. Pearson, Niels Halama, Dirk Jäger, Jeremias Krause, Sven H. Loosen, Alexander Marx, Peter Boor, Frank Tacke, Ulf Peter Neumann,
Heike I. Grabsch, Takaki Yoshikawa, Hermann Brenner, Jenny Chang-Claude,
Michael Hoffmeister, Christian Trautwein, Tom Luedde (2019) Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, https://www.nature.com/articles/s41591-019-0462-y

Weitere Informationen:

http://www.nature.com/articles/s41591-019-0462-y
http://www.nct-heidelberg.de

Dr. Friederike Fellenberg | idw - Informationsdienst Wissenschaft

Further reports about: CANCER Centrum für Tumorerkrankungen DKFZ MSI RWTH colorectal cancer immunotherapy

More articles from Life Sciences:

nachricht If Machines Could Smell ...
19.07.2019 | Fraunhofer-Institut für Produktionstechnik und Automatisierung IPA

nachricht Algae-killing viruses spur nutrient recycling in oceans
18.07.2019 | Rutgers University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Better thermal conductivity by adjusting the arrangement of atoms

Adjusting the thermal conductivity of materials is one of the challenges nanoscience is currently facing. Together with colleagues from the Netherlands and Spain, researchers from the University of Basel have shown that the atomic vibrations that determine heat generation in nanowires can be controlled through the arrangement of atoms alone. The scientists will publish the results shortly in the journal Nano Letters.

In the electronics and computer industry, components are becoming ever smaller and more powerful. However, there are problems with the heat generation. It is...

Im Focus: First-ever visualizations of electrical gating effects on electronic structure

Scientists have visualised the electronic structure in a microelectronic device for the first time, opening up opportunities for finely-tuned high performance electronic devices.

Physicists from the University of Warwick and the University of Washington have developed a technique to measure the energy and momentum of electrons in...

Im Focus: Megakaryocytes act as „bouncers“ restraining cell migration in the bone marrow

Scientists at the University Würzburg and University Hospital of Würzburg found that megakaryocytes act as “bouncers” and thus modulate bone marrow niche properties and cell migration dynamics. The study was published in July in the Journal “Haematologica”.

Hematopoiesis is the process of forming blood cells, which occurs predominantly in the bone marrow. The bone marrow produces all types of blood cells: red...

Im Focus: Artificial neural network resolves puzzles from condensed matter physics: Which is the perfect quantum theory?

For some phenomena in quantum many-body physics several competing theories exist. But which of them describes a quantum phenomenon best? A team of researchers from the Technical University of Munich (TUM) and Harvard University in the United States has now successfully deployed artificial neural networks for image analysis of quantum systems.

Is that a dog or a cat? Such a classification is a prime example of machine learning: artificial neural networks can be trained to analyze images by looking...

Im Focus: Extremely hard yet metallically conductive: Bayreuth researchers develop novel material with high-tech prospects

An international research group led by scientists from the University of Bayreuth has produced a previously unknown material: Rhenium nitride pernitride. Thanks to combining properties that were previously considered incompatible, it looks set to become highly attractive for technological applications. Indeed, it is a super-hard metallic conductor that can withstand extremely high pressures like a diamond. A process now developed in Bayreuth opens up the possibility of producing rhenium nitride pernitride and other technologically interesting materials in sufficiently large quantity for their properties characterisation. The new findings are presented in "Nature Communications".

The possibility of finding a compound that was metallically conductive, super-hard, and ultra-incompressible was long considered unlikely in science. It was...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on UV LED Technologies & Applications – ICULTA 2020 | Call for Abstracts

24.06.2019 | Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

 
Latest News

Heat flow through single molecules detected

19.07.2019 | Physics and Astronomy

Heat transport through single molecules

19.07.2019 | Physics and Astronomy

Welcome Committee for Comets

19.07.2019 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>